STOCK TITAN

111, Inc. Announces Change to Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
management

111, Inc. (NASDAQ: YI) announced changes to its Board of Directors on November 4, 2024. Dr. Leon Lian Yong Chen has resigned from his director position for personal reasons, effective immediately. The company has appointed Mr. Yang "Luke" Chen, currently serving as Senior Finance Executive, as the new director. Dr. Chen had served on the board since May 2019. The company's Executive Chairman, Mr. Gang Yu, expressed gratitude for Dr. Chen's contributions and welcomed Luke Chen, highlighting his financial expertise and understanding of the business as valuable assets for the company's strategic initiatives.

111, Inc. (NASDAQ: YI) ha annunciato cambiamenti nel suo Consiglio di Amministrazione il 4 novembre 2024. Il Dr. Leon Lian Yong Chen si è dimesso dalla sua posizione di direttore per motivi personali, con effetto immediato. L'azienda ha nominato Mr. Yang "Luke" Chen, attualmente in veste di Senior Finance Executive, come nuovo direttore. Il Dr. Chen era membro del consiglio dal maggio 2019. Il Presidente Esecutivo dell'azienda, Mr. Gang Yu, ha espresso gratitudine per il contributo del Dr. Chen e ha dato il benvenuto a Luke Chen, sottolineando la sua esperienza finanziaria e comprensione del business come risorse preziose per le iniziative strategiche dell'azienda.

111, Inc. (NASDAQ: YI) anunció cambios en su Junta Directiva el 4 de noviembre de 2024. El Dr. Leon Lian Yong Chen ha renunciado a su puesto de director por razones personales, con efecto inmediato. La compañía ha designado a Mr. Yang "Luke" Chen, quien actualmente se desempeña como Ejecutivo Financiero Senior, como el nuevo director. El Dr. Chen había estado en la junta desde mayo de 2019. El Presidente Ejecutivo de la compañía, Mr. Gang Yu, expresó su agradecimiento por las contribuciones del Dr. Chen y dio la bienvenida a Luke Chen, destacando su experiencia financiera y comprensión del negocio como activos valiosos para las iniciativas estratégicas de la empresa.

111 Inc. (NASDAQ: YI)은 2024년 11월 4일 이사회 변경을 발표했습니다. 레온 리안 용 첸 박사는 개인적인 이유로 즉시 이사직에서 사임했습니다. 회사는 현재 수석 재무 임원으로 재직 중인 양 "루크" 첸을 새로운 이사로 임명했습니다. 첸 박사는 2019년 5월부터 이사회에서 활동해왔습니다. 회사의 이사회 의장인 강 유 씨는 첸 박사의 기여에 감사의 뜻을 전하며, 루크 첸을 환영하며 그의 재무 전문성과 기업에 대한 이해가 회사의 전략적 이니셔티브에 가치 있는 자산이라고 강조했습니다.

111, Inc. (NASDAQ: YI) a annoncé des changements dans son Conseil d'Administration le 4 novembre 2024. Le Dr Leon Lian Yong Chen a démissionné de son poste de directeur pour des raisons personnelles, avec effet immédiat. L'entreprise a nommé M. Yang "Luke" Chen, actuellement Senior Finance Executive, comme nouveau directeur. Le Dr Chen faisait partie du conseil depuis mai 2019. Le Président Exécutif de l'entreprise, M. Gang Yu, a exprimé sa gratitude pour les contributions du Dr Chen et a souhaité la bienvenue à Luke Chen, soulignant que son expertise financière et sa compréhension du secteur sont des atouts précieux pour les initiatives stratégiques de l'entreprise.

111, Inc. (NASDAQ: YI) gab am 4. November 2024 Änderungen im Vorstand bekannt. Dr. Leon Lian Yong Chen hat aus persönlichen Gründen mit sofortiger Wirkung von seiner Direktorposition zurückgetreten. Das Unternehmen hat Mr. Yang "Luke" Chen, der derzeit als Senior Finance Executive fungiert, zum neuen Direktor ernannt. Dr. Chen war seit Mai 2019 im Vorstand tätig. Der Vorstandsvorsitzende des Unternehmens, Mr. Gang Yu, drückte seine Dankbarkeit für die Beiträge von Dr. Chen aus und begrüßte Luke Chen, während er dessen finanzielle Expertise und Verständnis des Geschäfts als wertvolle Vermögenswerte für die strategischen Initiativen des Unternehmens hervorhob.

Positive
  • Appointment of Senior Finance Executive to board indicates strong internal succession planning
  • New director brings financial expertise and business understanding to the board
Negative
  • Departure of experienced board member who served since 2019

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang "Luke" Chen, currently serving as the Company's Senior Finance Executive, as a new director, effective November 4, 2024.

Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. "I am grateful to Dr. Chen for his significant contributions during his term of office. His knowledge and advice have been invaluable in propelling our goals and strategies for long-term achievements. On behalf of the board, I extend best wishes to Dr. Chen and look forward to further collaborating with him in the future," said Mr. Gang Yu, Co-Founder and Executive Chairman of the Company.

Regarding the appointment of Mr. Yang "Luke" Chen, Mr. Gang Yu added, "We are delighted to welcome Luke to our board of directors. His extensive financial expertise and deep understanding of our business will be instrumental as we continue to drive our strategic initiatives forward. I am confident that his leadership and insights will contribute to our ongoing success and growth."

Forward-Looking Statements

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future,"" "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

About 111, Inc.

111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.

For more information on 111, please visit: http://ir.111.com.cn/

 

Cision View original content:https://www.prnewswire.com/news-releases/111-inc-announces-change-to-board-of-directors-302294966.html

SOURCE 111, Inc.

FAQ

Who replaced Dr. Leon Lian Yong Chen on 111, Inc.'s (YI) board of directors?

Mr. Yang 'Luke' Chen, the company's Senior Finance Executive, was appointed as the new director of 111, Inc. (YI) effective November 4, 2024.

When did Dr. Leon Lian Yong Chen resign from 111, Inc.'s (YI) board?

Dr. Leon Lian Yong Chen resigned from 111, Inc.'s board effective November 4, 2024.

How long did Dr. Leon Lian Yong Chen serve on 111, Inc.'s (YI) board?

Dr. Leon Lian Yong Chen served on 111, Inc.'s board from May 2019 until November 4, 2024.

111, Inc. American Depositary Shares

NASDAQ:YI

YI Rankings

YI Latest News

YI Stock Data

52.26M
33.71M
16.16%
23.9%
0.04%
Medical Distribution
Healthcare
Link
United States of America
Shanghai